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Dr Kenton J. Zehr (Temple, Tex). To the AATS Program Com-
mittee, moderators, and the Mayo Clinic group:
Thank you for the opportunity to discuss this report and the priv-
ilege of reviewing the full study before the meeting.
Dr Iturra and the Mayo Clinic group have presented a unique
group of primarily elderly intermediate-risk group patients under-
going aortic valve replacement (AVR) or AVR plus CABG during
the recent decade. Despite an STS risk score of 4% to 8%, they
observed mortality of 2.8%. One remembers back to a report
from the same institution presented by Drs Dwight McGoon and
Emerson Moffit for the first 100 consecutive AVRs with a Starr-
Edwards valvewithout a single mortality. Good therapies find their
way. This is another report attesting to the safety and efficacy of
SAVR.
This study raises the question of the presumed equipoise to
TAVR in this group of intermediate-risk patients, and I would
rhetorically ask: ‘‘where is the evidence for equipoise?’’ You132 The Journal of Thoracic and Cardiovascular Surghave seen the low rates of complications in this presented series,
with a postoperative length of stay of 7 days and an 8.2% read-
mission rate at 30 days. Most of us can agree that the PARTNER
trial strongly confirmed the benefits of TAVR in inoperable pa-
tients and suggested equipoise for high-risk surgical patients,
but it came at a significant price. If one reviews the briefing
for the Food and Drug Administration regarding the experience
with the SAPIEN valve in the nonoperative cohort, there were
8 device malfunctions, 4 patients required an additional valve,
and 7 patients never received a valve because of access issues
and were excluded from the study. In the high-risk cohort study
in the PARTNER trial, 4 intraprocedural deaths occurred, 3 in the
TAVR group and 1 in the AVR group. Also, in 16 patients, the
procedure was aborted or converted to AVR because of intrapro-
cedural findings, 7 patients required >1 valve (2 because of
embolization and 5 because of paravalvular leak), and 5 addi-
tional valve embolizations occurred. Cardiac mortality was the
same in both groups, but the stroke rate was double. In the
Danish STACCATO trial, the study was terminated.
DrWoo. Could we ask you to ask the questions, we are short on
time.
Dr Zehr. I have just 1 question.
I want to present a little bit of our recent data. We started using
TAVR, and we have treated 34 patients within 8 months. We have
had no intraprocedural deaths, but we have had 3 deaths within 30
days. They also come at a price: a few minor vascular complica-
tions, 1 stroke, and 2 patients who required median sternotomy
for tamponade. So, we recognize the value of TAVR, but we
believe it is a real operation with real complications and in no
way have we concluded that current equipoise exists for interme-
diate-risk patients.
So, I have 1 question. How is your group addressing the pressure
to perform TAVR in these intermediate-risk patients in lieu of your
results and the current recommendations from the Food and Drug
Administration and Centers for Medicare & Medicaid Services?
Thank you very much.
Dr Iturra. Thank you for your comments and question.
The clinical records and imaging studies of each patient being
considered for either Food and Drug Administration transcatheter
trials or commercially available TAVR devices are discussed by a
multidisciplinary heart team at the Mayo Clinic. When a patient is
being considered for randomization, we use the currently available
data and solicit the opinions of all heart team members to arrive at
a determination of whether equipoise exists. If so, we provide full
disclosure of the indications, risks, benefits, and alternatives of
SAVR versus transcatheter valve therapy to each patient to allow
them to make an informed decision.ery c January 2014
